Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Ovarian Cancer.

BC-3195 is under clinical development by BioCity Biopharma and currently in Phase I for Metastatic Ovarian Cancer.

To our knowledge, there are no published clinical data on DW-MRI assessment of chemotherapy response in ovarian cancer, or on the effect of previous treatment on ADC values. The multifocality and ...

There is a significant overlap between some symptoms of ovarian cancer, irritable bowel syndrome (IBS) and premenstrual ...

The top 5 ovarian cancer articles of 2024 covered topics such as the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early ...

Ovarian cancer cells exploit cell competition by altering Flower protein isoforms in stromal cells, promoting tumor survival ...

Discover crucial early warning signs of ovarian cancer that may surface during or after meals. Learn about symptoms, risk ...